What were the most frequently reported adverse reactions to Cayston (aztreonam lysine) in placebo-controlled cystic fibrosis studies?

In two Phase 3 placebo-controlled cystic fibrosis studies with 28 days of Cayston (aztreonam lysine), the most frequent adverse reactions were cough (58%), nasal congestion (18%), wheezing (15%), pharyngolaryngeal pain (13%), pyrexia (12%) and dyspnoea (10%).